Year: 2025
Type: article
Study design: Case Report
Abstract: Introduction: Apalutamide, an androgen receptor antagonist for prostate cancer, rarely causes drug-induced hypersensitivity syndrome (DIHS). Case Presentation: A 75-year-old male with prostate cancer and multiple bone metastases developed grade 2 rash and grade 3 liver dysfunction according to the Common Terminology Criteria for Adverse Events (CTCAE) 3 weeks after starting apalutamide with a GnRH antagonist, followed by a 3-day fever. Ten days later, symptoms worsened to grade 3 rash and grade 4 liver dysfunction. He met five diagnostic criteria for DIHS. Hormonal therapy was discontinued, and prednisolone plus intravenous immunoglobulin (IVIG) was administered. Fatigue resolved within 2 days, rash by day 6, and liver function improved to grade 2 by day 10. The patient is currently on abiraterone and a GnRH antagonist without adverse events. Conclusion: This report highlights the importance of caution and regular blood tests when using apalutamide owing to the risk of DIHS.
Source: IJU Case Reports
DOI: 10.1002/iju5.70085
Authors: Yuki Tanaka, Yui Fujimura, Koya Morishita, Yuta Kashiwagi, Satoshi Katsuno, Tatsuya Nagai
Institution: Okazaki City Hospital
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,960
OpenAlex ID: W4413415988